These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9412400)

  • 21. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from patients in primary hospitals in Shanghai from 2007 to 2010].
    Zhou CM; Hu BJ; Gao XD; Bao R; Xie HM; Huang SL; Tao LL; He LX
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 May; 36(5):346-50. PubMed ID: 24047808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns.
    File TM; Benninger MS; Jacobs MR
    Clin Lab Med; 2004 Jun; 24(2):531-51. PubMed ID: 15177852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Importance of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia].
    Sáez-Llorens X; Castaño E; Wubbel L; Castrejón MM; de Morales I; Vallarino D; de Atencio I; Muñiz L; Olsen K; McCracken GH
    Rev Med Panama; 1998 Sep; 23(2):27-33. PubMed ID: 11214557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media.
    Ghaffar F; Muniz LS; Katz K; Reynolds J; Smith JL; Davis P; Friedland IR; McCracken GH
    Clin Infect Dis; 2000 Oct; 31(4):875-80. PubMed ID: 11049764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The viewpoint of the microbiologist].
    Quentin C
    Presse Med; 1998 Sep; 27 Suppl 4():12-3. PubMed ID: 9798477
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
    Sethi S; Breton J; Wynne B
    Antimicrob Agents Chemother; 2005 Jan; 49(1):153-60. PubMed ID: 15616290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.
    Sader HS; Jacobs MR; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):5S-12S. PubMed ID: 17292577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
    Sunakawa K; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain.
    Isla A; Trocóniz IF; Canut A; Labora A; Martín-Herrero JE; Pedraz JL; Gascón AR
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):167-73. PubMed ID: 21334779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model].
    Gómez-Lus ML; García Y; Valero E; Amores R; Fuentes F
    Rev Esp Quimioter; 2000 Sep; 13(3):306-13. PubMed ID: 11086282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
    Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
    J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antibiotic resistance of S. pneumoniae and H. influenzae strains isolated from patients with community acquired respiratory tract infections. BACTRO multicenter, multidisciplinary study].
    Tudose C; Bumbăcea D; Bogdan M;
    Pneumologia; 2011; 60(1):30-5. PubMed ID: 21548198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prospective and comparative study between cefuroxime, ceftriaxone and amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia].
    Sánchez ME; Gómez J; Gómez Vargas J; Baños V; Ruiz Gómez J; Muñoz L; Simarro E; Soto MC; Canteras M; Valdés M
    Rev Esp Quimioter; 1998 Jun; 11(2):132-8. PubMed ID: 9795298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections.
    Bantar C; Nicola F; Fernandez Canigia L; Arenoso HJ; Soutric J; Montoto M; Blanco M; Smayevsky J; Jasovich A
    J Chemother; 2000 Jun; 12(3):223-7. PubMed ID: 10877517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
    Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
    J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Penicillin and gentamicin therapy vs amoxicillin/clavulanate in severe hypoxemic pneumonia.
    Bansal A; Singhi SC; Jayashree M
    Indian J Pediatr; 2006 Apr; 73(4):305-9. PubMed ID: 16816491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
    Lode H; Magyar P; Muir JF; Loos U; Kleutgens K;
    Clin Microbiol Infect; 2004 Jun; 10(6):512-20. PubMed ID: 15191378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.